AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

China is among the largest pharma markets globally—and a major market for AstraZeneca specifically. Last year, the pharma ...

Pharmaceutical giant AstraZeneca said that the head of its China operations had been detained, after reports the firm was ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Pharmaceutical giant AstraZeneca has confirmed that Leon Wang, the head of its China operations, had been detained.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

AstraZeneca plans to hire over 800 in Singapore for engineering, quality, technical services, and supply chain roles at its ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...